Bloomberg Being a big drug company isn’t what it used to be. The largest drugmakers are finding it more difficult to charge high prices for a range of medications, their latest quarterly results show. That’s raising the pressure to pump up sales volumes and find lucrative new treatments for niche markets. “You had an environment in which you could ...
Read More »